Anti-angiogenic therapy via cationic liposome-mediated systemic siRNA delivery

International Journal of Pharmaceutics

Volumn 422, Issue 1-2, 2012, Pages 280-289

  Tagami, Tatsuaki ^a   Suzuki, Takuya ^a   Matsunaga, Mariko ^a   Nakamura, Kazuya ^a   Moriyoshi, Naoto ^a   Ishida, Tatsuhiro ^a   Kiwada, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Anti angiogenic therapy; Argonaute2 (Ago2); Cationic liposome; PEG coated siRNA lipoplex; Small interfering RNA (siRNA)

Indexed keywords

ARGONAUTE 2 PROTEIN; CATIONIC LIPOSOME; LIPOPLEX; LIPOSOME; MACROGOL; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

AIR SAC; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING INDEX; CONTROLLED STUDY; CYTOTOXICITY; DORSAL AIR SAC; LEWIS CARCINOMA; LIPID COMPOSITION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; SYSTEMIC THERAPY; VASCULAR TUMOR;

AIR SACS; ANIMALS; ARGONAUTE PROTEINS; CARCINOMA, LEWIS LUNG; CATIONS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CHOLESTEROL; ETHANOLAMINES; GENE THERAPY; LIPIDS; LIPOSOMES; MALE; MICE; MYRISTATES; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TIME FACTORS; TRANSFECTION; TUMOR BURDEN;

EID: 84655160875     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.10.059     Document Type: Article

References (37)

1. A. Abu-Lila, T. Suzuki, Y. Doi, T. Ishida, and H. Kiwada Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model J. Control Release 134 2009 18 25
2. A.S. Abu Lila, S. Kizuki, Y. Doi, T. Suzuki, T. Ishida, and H. Kiwada Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model J. Control Release 137 2009 8 14
3. S. Akhtar, and I.F. Benter Nonviral delivery of synthetic siRNAs in vivo J. Clin. Invest. 117 2007 3623 3632 (Pubitemid 350224068)
4. C. Allen, N. Dos Santos, R. Gallagher, G.N. Chiu, Y. Shu, W.M. Li, S.A. Johnstone, A.S. Janoff, L.D. Mayer, M.S. Webb, and M.B. Bally Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol) Biosci. Rep. 22 2002 225 250 (Pubitemid 35222733)
5. T.M. Allen, and P.R. Cullis Drug delivery systems: entering the mainstream Science 303 2004 1818 1822 (Pubitemid 38374867)
6. T. Asai, Y. Suzuki, S. Matsushita, S. Yonezawa, J. Yokota, Y. Katanasaka, T. Ishida, T. Dewa, H. Kiwada, M. Nango, and N. Oku Disappearance of the angiogenic potential of endothelial cells caused by Argonaute2 knockdown Biochem. Biophys. Res. Commun. 368 2008 243 248
7. J.M. Barichello, S. Kizuki, T. Tagami, T. Asai, T. Ishida, H. Kikuchi, N. Oku, and H. Kiwada Agitation during lipoplex formation improves the gene knockdown effect of siRNA Int. J. Pharm. 410 2011 153 160
8. G.R. Bartlett Colorimetric assay methods for free and phosphorylated glyceric acids J. Biol. Chem. 234 1959 469 471
9. R.B. Campbell, B. Ying, G.M. Kuesters, and R. Hemphill Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics J. Pharm. Sci. 98 2009 411 429
10. R.B. Campbell, D. Fukumura, E.B. Brown, L.M. Mazzola, Y. Izumi, R.K. Jain, V.P. Torchilin, and L.L. Munn Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors Cancer Res. 62 2002 6831 6836 (Pubitemid 35424069)
11. P.Y. Chien, J. Wang, D. Carbonaro, S. Lei, B. Miller, S. Sheikh, S.M. Ali, M.U. Ahmad, and I. Ahmad Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo Cancer Gene Ther. 12 2005 321 328 (Pubitemid 40315192)
12. C.R. Dass Improving anti-angiogenic therapy via selective delivery of cationic liposomes to tumour vasculature Int. J. Pharm. 267 2003 1 12 (Pubitemid 37352945)
13. H.K. de Wolf, C.J. Snel, F.J. Verbaan, R.M. Schiffelers, W.E. Hennink, and G. Storm Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration Int. J. Pharm. 331 2007 167 175 (Pubitemid 46216670)
14. S.M. Elbashir, J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells Nature 411 2001 494 498 (Pubitemid 32494397)
15. J. Folkman Tumor angiogenesis: therapeutic implications N. Engl. J. Med. 285 1971 1182 1186
16. H. Hatakeyama, H. Akita, and H. Harashima A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma Adv. Drug Deliv. Rev. 63 2011 152 160
17. R.V. Iozzo, and J.D. San Antonio Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena J. Clin. Invest. 108 2001 349 355 (Pubitemid 32730778)
18. T. Ishida, M. Harada, X.Y. Wang, M. Ichihara, K. Irimura, and H. Kiwada Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes J. Control Release 105 2005 305 317 (Pubitemid 40941995)
19. T. Ishida, D.L. Iden, and T.M. Allen A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs FEBS Lett. 460 1999 129 133 (Pubitemid 29479257)
20. T. Kobayashi, T. Ishida, Y. Okada, S. Ise, H. Harashima, and H. Kiwada Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells Int. J. Pharm. 329 2007 94 102 (Pubitemid 44937528)
21. M.R. Lares, J.J. Rossi, and D.L. Ouellet RNAi and small interfering RNAs in human disease therapeutic applications Trends Biotechnol. 28 2011 570 579
22. T.S. Levchenko, R. Rammohan, A.N. Lukyanov, K.R. Whiteman, and V.P. Torchilin Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating Int. J. Pharm. 240 2002 95 102 (Pubitemid 34607706)
23. J. Liu, M.A. Carmell, F.V. Rivas, C.G. Marsden, J.M. Thomson, J.J. Song, S.M. Hammond, L. Joshua-Tor, and G.J. Hannon Argonaute2 is the catalytic engine of mammalian RNAi Science 305 2004 1437 1441 (Pubitemid 39167657)
24. J. Lu, M. Liong, Z. Li, J.I. Zink, and F. Tamanoi Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals Small 6 2010 1794 1805
25. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Control Release 65 2000 271 284 (Pubitemid 30122932)
26. G. Meister, M. Landthaler, A. Patkaniowska, Y. Dorsett, G. Teng, and T. Tuschl Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs Mol. Cell 15 2004 185 197 (Pubitemid 38950966)
27. S. Mishra, P. Webster, and M.E. Davis PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles Eur. J. Cell Biol. 83 2004 97 111 (Pubitemid 38765217)
28. C. Phalon, D.D. Rao, and J. Nemunaitis Potential use of RNA interference in cancer therapy Expert Rev. Mol. Med. 12 2010 e26
29. S. Ran, and P.E. Thorpe Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy Int. J. Radiat. Oncol. Biol. Phys. 54 2002 1479 1484 (Pubitemid 35380052)
30. K. Remaut, B. Lucas, K. Braeckmans, J. Demeester, and S.C. De Smedt PEGylation of liposomes favours the endosomal degradation of the delivered phosphodiester oligonucleotides J. Control Release 117 2007 255 266
31. R.M. Schiffelers, M.H. Fens, A.P. Janssen, G. Molema, and G. Storm Liposomal targeting of angiogenic vasculature Curr. Drug Deliv. 2 2005 363 368 (Pubitemid 41277768)
32. S. Spagnou, A.D. Miller, and M. Keller Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA Biochemistry 43 2004 13348 13356 (Pubitemid 39391135)
33. T. Tagami, K. Hirose, J.M. Barichello, T. Ishida, and H. Kiwada Global gene expression profiling in cultured cells is strongly influenced by treatment with siRNA-cationic liposome complexes Pharm. Res. 25 2008 2497 2504
34. T. Tagami, K. Nakamura, T. Shimizu, T. Ishida, and H. Kiwada Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production J. Control Release 137 2009 234 240
35. T. Tagami, T. Suzuki, K. Hirose, J.M. Barichello, N. Yamazaki, T. Asai, N. Oku, T. Ishida, and H. Kiwada Argonaute2 is a potential target for siRNA-based cancer therapy for HT1080 human fibrosarcoma Drug Deliv. Transl. Res. 1 2011 277 288
36. Y. Takakura, M. Nishikawa, F. Yamashita, and M. Hashida Influence of physicochemical properties on pharmacokinetics of non-viral vectors for gene delivery J. Drug Target 10 2002 99 104 (Pubitemid 34272377)
37. G. Thurston, J.W. McLean, M. Rizen, P. Baluk, A. Haskell, T.J. Murphy, D. Hanahan, and D.M. McDonald Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice J. Clin. Invest. 101 1998 1401 1413 (Pubitemid 28166838)